Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus LIQUAEMIN SODIUM PRESERVATIVE FREE.
LIQUAEMIN LOCK FLUSH vs LIQUAEMIN SODIUM PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
None Documented
None Documented
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Category C
Category C
Anticoagulant
Anticoagulant